

Editor-in-Chief:

S.J. Enna University of Kansas, USA

Editors:

J.G. Piette University of Liège, Belgium
G.Z. Feuerstein Farmacon, LLC, USA
M. Williams Northwestern University, USA

Commentary Editor:

Biochemical Pharmacology Editorial Office:

University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 4016, Kansas City, Kansas 66160, USA, Tel: +1-913-588-7533, Fax: +1-913-588-7373, Email: BP@kumc.edu

EDITORIAL ADVISORY BOARD:

Antibiotics & Chemotherapeutics

B.B. Aggarwal University of Texas M.D. Anderson Cancer Center, USA
C. Bailly Institut de Recherche Pierre Fabre, France
S. Ceruti University of Milano, Italy
B.S. Cummings University of Georgia, USA
E. De Clercq Catholic University of Leuven, Belgium
M. Diederich Cancer and Blood Disease Research Foundation, Luxembourg
J.D. Docquier University of Siena, Italy
C. Elferink University of Texas Medical Branch, USA
F.A.E. Kruyt University Medical Center Groningen, The Netherlands
H.P. Gerber Pfizer Biotherapeutics, USA
D.A. Gewirtz Virginia Commonwealth University Massey Cancer Center, USA
O. Handa Kyoto Prefectural University of Medicine, Japan
B.A. Ruggeri Cephalon, Inc., USA
G.L. Russo National Research Council, Italy
C. Michiels University of Namur, Belgium
S. S. Singhal University of North Texas Health Science Center, USA
K. Smalley Moffitt Cancer Center, USA
B.A. Teicher Genzyme Corporation, USA
K.D. Tew Medical University of South Carolina, USA
F. Zunino National Institute for the Study and Cure of Tumors, Italy

Cardiovascular

J.J. Badimon Mount Sinai School of Medicine, USA
M.R. Bennett University of Cambridge, UK
Y-H. Feng Uniformed Services University of the Health Sciences, USA
B. M. Frey-von Matt University of Bern, Switzerland
R.A. Khalil Harvard Medical School, USA
D. Miller Wyeth Research, USA
D. Newby University of Edinburgh, UK
E.H. Ohlstein Venuvics Pharmaceuticals, USA
R.G. Schaub Archemix Corporation, USA
A.M. Schmidt Columbia University Medical Center, New York, USA
B. Staels University of Lille II, France
J. Winaver Technion, IIT, Israel
R.J. Winquist Vertex Pharmaceuticals, USA

Metabolic Disorders and Endocrinology

N. Chattopadhyay Central Drug Research Institute, India
J.R. Colca Kalamazoo Metabolic Research, USA
A. Kowluru Wayne State University, USA
J. Pierre INSERM U93-01, France
M.E. Poirot INSERM U563, France
C.D. Sutherland University of Dundee, UK

Inflammation & Immunopharmacology

M.J. Alcaraz University of Valencia, Spain
G.F. Babcock University of Cincinnati Medical Center, USA
R. Beyaert University of Gent, Belgium
A. Bowie Trinity College, Ireland
F. D'Acquisto William Harvey Research Institute, UK
J. El Benna Université Paris (INSERM), France
M.P. Fink Logical Therapeutics, USA
K.B. Glaser Abbott Laboratories, USA
O. Léo Université Libre de Bruxelles, Belgium
J.-H. Lai National Defense Medical Center, Taiwan, ROC
J.J. Moreno University of Barcelona, Spain
M. Mousli University of Strasbourg, France
D. R. Webb Celgene Research, USA

Neuropharmacology

J. Bergman Harvard Medical School, USA
D.C. Bertrand University of Geneva, Switzerland
R.A.J. Challiss University of Leicester, UK
C. Forray Lundbeck Research USA
E.D. Hall University of Kentucky Medical Center, USA
M.F. Jarvis Abbott Laboratories, USA
M.J. Kuhar Emory University, USA
R. Lewis University of Queensland, Australia
M.J. Marino Merck & Co., Inc., USA
P. McGonigle PsychoGenics, USA
H. Möhler University of Zurich, Federal Institute of Technology, Switzerland
A. Schousboe Danish University of Pharmaceutical Sciences, Denmark
R.D. Speakman Harvard University Medical School, USA
D.J. Trigg State University of New York - Buffalo, USA
D. Weinschenker Emory University, USA
J.M. Witkin Lilly Corporate Center, USA

Pharmacokinetics & Drug Metabolism

K-I. Inui Kyoto University Hospital, Japan
D.E. Mager University at Buffalo, SUNY, USA

Toxicology

K.W. Bock University of Tübingen, Germany
B.J. Day National Jewish Medical and Research Center, USA